Advisors Preferred LLC Sells 4,225 Shares of Moderna, Inc. (NASDAQ:MRNA)

Advisors Preferred LLC reduced its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 22.8% in the fourth quarter, HoldingsChannel.com reports. The firm owned 14,306 shares of the company’s stock after selling 4,225 shares during the period. Advisors Preferred LLC’s holdings in Moderna were worth $601,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. State Street Corp increased its stake in shares of Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after buying an additional 1,823,276 shares during the period. Wellington Management Group LLP grew its holdings in shares of Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after acquiring an additional 906,114 shares during the period. Two Sigma Advisers LP bought a new position in shares of Moderna in the 3rd quarter worth approximately $23,825,000. International Assets Investment Management LLC lifted its stake in shares of Moderna by 10,687.1% in the 3rd quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock valued at $21,353,000 after purchasing an additional 316,552 shares during the period. Finally, Douglas Lane & Associates LLC boosted its position in shares of Moderna by 62.9% during the fourth quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock valued at $32,175,000 after purchasing an additional 298,715 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Insider Activity

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares in the company, valued at approximately $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders sold 2,664 shares of company stock valued at $115,210. Corporate insiders own 15.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on MRNA shares. Piper Sandler reiterated an “overweight” rating and issued a $69.00 price objective (down previously from $115.00) on shares of Moderna in a report on Monday, November 18th. The Goldman Sachs Group lowered shares of Moderna from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. Argus cut shares of Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Friday, November 8th. Finally, Jefferies Financial Group cut their price target on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research note on Tuesday, October 15th. Four research analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $67.26.

Moderna Trading Down 3.0 %

MRNA opened at $32.60 on Friday. Moderna, Inc. has a 52-week low of $31.94 and a 52-week high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The business has a fifty day moving average of $40.22 and a 200 day moving average of $58.87.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the company earned ($1.39) EPS. As a group, equities analysts predict that Moderna, Inc. will post -8.95 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.